What is the equity of Bio-Techne this year?
Bio-Techne has equity of 1.97 B USD this year.
Bio-Techne Equity 2024
Bio-Techne Equity
1.97 B USD
Bio-Techne Dividend yield
0.68 %
Ticker
TECH
ISIN
US09073M1045
WKN
A12ENG
In 2024, Bio-Techne's equity was 1.97 B USD, a 15.55% increase from the 1.7 B USD equity in the previous year.
Bio-Techne Aktienanalyse
What does Bio-Techne do?
Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Bio-Techne's Equity
Bio-Techne's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bio-Techne's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Bio-Techne's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Bio-Techne's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Bio-Techne’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Bio-Techne Stock
What was the equity of Bio-Techne compared to the previous year?
The equity of Bio-Techne has increased/decreased by 15.55% increased compared to the previous year.
What impact does a high equity have on investors of Bio-Techne?
A high equity is advantageous for investors of Bio-Techne as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Bio-Techne?
A low equity can be a risk for investors of Bio-Techne, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Bio-Techne affect the company?
An increase in equity of Bio-Techne can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Bio-Techne affect the company?
A reduction in equity of Bio-Techne can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Bio-Techne?
Some factors that can affect the equity of Bio-Techne include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Bio-Techne so important for investors?
The equity of Bio-Techne is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Bio-Techne take to change the equity?
To change equity, Bio-Techne can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Bio-Techne pay?
Over the past 12 months, Bio-Techne paid a dividend of 0.56 USD . This corresponds to a dividend yield of about 0.68 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.56 USD.
What is the dividend yield of Bio-Techne?
The current dividend yield of Bio-Techne is 0.68 %.
When does Bio-Techne pay dividends?
Bio-Techne pays a quarterly dividend. This is distributed in the months of December, December, March, June.
How secure is the dividend of Bio-Techne?
Bio-Techne paid dividends every year for the past 0 years.
What is the dividend of Bio-Techne?
For the upcoming 12 months, dividends amounting to 0.56 USD are expected. This corresponds to a dividend yield of 0.69 %.
In which sector is Bio-Techne located?
Bio-Techne is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bio-Techne from 5/24/2024 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 5/10/2024.
When did Bio-Techne pay the last dividend?
The last dividend was paid out on 5/24/2024.
What was the dividend of Bio-Techne in the year 2023?
In the year 2023, Bio-Techne distributed 1.043 USD as dividends.
In which currency does Bio-Techne pay out the dividend?
The dividends of Bio-Techne are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Bio-Techne
Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
